New drug targets for type 2 diabetes and the metabolic syndrome

By D. Moller. Nature, 2001

1,074 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Fibroblast growth factor 21 corrects obesity in mice. (2008, background): “The latter observation provides preclinical evidence to suggest that future attempts to develop FGF21 as a therapy for type 2 diabetes will not be hampered by edema as a side effect, a common adverse consequence seen with some antidiabetic therapies (15).”
CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. (2004, background): “The Journal of Clinical Investigation | January 2004 | Volume 113 | Number 2 275 2 diabetes, obesity, and the metabolic syndrome (26, 27), but the locations of the regulatory AMP- and ATP-binding sites (the most likely binding sites for activators) have not been characterized.”
FGF-21 as a novel metabolic regulator. (2005, background): “Discussion Several secreted polypeptides, including insulin, glucagon-like peptide–1 (GLP-1), adiponectin, and others are ultimately involved in the regulation of glucose homeostasis, which thus makes them clinically relevant pharmacological agents or attractive candidates for novel medicines for th”